MabCampath viste sig at være chlorambucil overlegent målt ved det primære endepunkt progressionsfri overlevelse (PFS) (se Figur 1).
MabCampath was shown to be superior to chlorambucil as measured by the primary endpoint progression free survival (PFS) (see Figure 1).